Welcome to our dedicated page for Vtv Therapeutics SEC filings (Ticker: VTVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding biotech disclosures isn鈥檛 easy鈥攅specially when vTv Therapeutics鈥� 10-K buries cash-burn data beside dense clinical trial tables. If you have ever typed 鈥渧Tv Therapeutics SEC filings explained simply鈥� into a search bar, you already know the struggle. Our platform turns those 200-page documents into concise, plain-English insights, so you can focus on what matters: how clinical milestones, licensing deals, and dilution risks shape VTVT鈥檚 future.
Stock Titan鈥檚 AI reads every submission the moment it appears on EDGAR and surfaces answers to questions professionals actually ask, such as 鈥渦nderstanding vTv Therapeutics SEC documents with AI鈥� or 鈥渧Tv Therapeutics quarterly earnings report 10-Q filing鈥攚here is R&D spend hiding?鈥�. You鈥檒l find:
- AG真人官方-time alerts for vTv Therapeutics Form 4 insider transactions real-time and detailed views of each vTv Therapeutics executive stock transactions Form 4.
- A side-by-side comparison tool that turns each vTv Therapeutics annual report 10-K simplified into year-over-year trendlines.
- Drill-downs that link every vTv Therapeutics earnings report filing analysis back to trial timelines and cash runway projections.
Need the latest update on trial recruitment or a new partnership? Our feed captures every vTv Therapeutics 8-K material events explained and highlights compensation shifts inside each vTv Therapeutics proxy statement executive compensation. Whether you鈥檙e tracking 鈥渧Tv Therapeutics insider trading Form 4 transactions鈥� or mapping liquidity between quarters, Stock Titan鈥檚 AI-powered summaries deliver clarity in minutes, not hours.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, led by cadisegliatin, a potential first-in-class liver-selective glucokinase activator in a Phase 3 trial. The FDA removed a clinical hold on the cadisegliatin program on March 14, 2025, the company reinitiated patient screening in May 2025, randomized the first participant on August 6, 2025, and shortened the CATT1 study from 12 to 6 months; top-line data are expected in the second half of 2026. The U.S. Patent Office allowed claims for a crystalline salt form of cadisegliatin in August 2025.
On the balance sheet as of June 30, 2025, vTv held $25.9 million in cash, had an accumulated deficit of $310.9 million, and reported a six-month net loss attributable to common shareholders of $11.1 million. There was no product revenue in H1 2025 (prior period included $1.0 million of collaboration revenue in H1 2024). The company completed a $51.0 million private placement in February 2024 and has an ATM program; however, management discloses substantial doubt about the company鈥檚 ability to continue as a going concern without additional financing.
FAQ
What is the current stock price of Vtv Therapeutics (VTVT)?
What is the market cap of Vtv Therapeutics (VTVT)?
